Evicenter
Skyrizi (risankizumab-rzaa) in Plaque psoriasis
Manufacturer
AbbVie Inc.
Prescribing information
Skyrizi (opens in a new tab)
Questions
47
Last updated

All questions

Clinical trials: Skyrizi (risankizumab-rzaa) in plaque psoriasis

18 questions · 9 sources

Study results

How effective is Skyrizi for plaque psoriasis at 16 weeks (UltIMMa-1 and UltIMMa-2)?

Applies to Adults with moderate-to-severe plaque psoriasis

Note: Trials PsO-1 and PsO-2 of the Prescribing Information enrolled 997 subjects, the combined enrollment of UltIMMa-1 (506) and UltIMMa-2 (491) on the Skyrizi HCP site, and report the same Week 16 rates in Table 8.

How many people on Skyrizi get completely clear skin (PASI 100)?

Applies to Adults with moderate-to-severe plaque psoriasis

Note: Table 8 columns are PsO-1 SKYRIZI (N=304), PsO-1 placebo (N=102), PsO-2 SKYRIZI (N=294), and PsO-2 placebo (N=98), in that order, each as n (%). Placebo was given only through Week 16.

Does Skyrizi keep skin clear at one year (PASI 90 at Week 52)?

Applies to Adults with moderate-to-severe plaque psoriasis

Note: Trials PsO-1 and PsO-2 of the Prescribing Information have the combined enrollment (997) of UltIMMa-1 and UltIMMa-2 on the Skyrizi HCP site. Placebo was given only through Week 16.

How quickly does Skyrizi start working for plaque psoriasis?

Applies to Adults with moderate-to-severe plaque psoriasis

Does Skyrizi relieve psoriasis itching, pain, and burning?

Applies to Adults with moderate-to-severe plaque psoriasis

How effective was Skyrizi compared with placebo in trial PsO-3 (IMMhance)?

Applies to Adults with moderate-to-severe plaque psoriasis

Note: The Prescribing Information reports a 507-subject placebo-controlled trial with withdrawal and re-treatment as PsO-3 (NCT02672852); the Skyrizi HCP safety page describes IMMhance as its Phase 3 placebo-controlled withdrawal and re-treatment study. Neither document names the trial both ways.

Does psoriasis come back if Skyrizi is stopped?

Applies to Adults with moderate-to-severe plaque psoriasis

Note: Only subjects originally on Skyrizi with sPGA 0 or 1 at Week 28 were re-randomized. The Prescribing Information reports a 507-subject placebo-controlled trial with withdrawal and re-treatment as PsO-3 (NCT02672852); the Skyrizi HCP safety page describes IMMhance as its Phase 3 placebo-controlled withdrawal and re-treatment study. Neither document names the trial both ways.

Does Skyrizi work for scalp psoriasis?

Applies to Adults with moderate-to-severe plaque psoriasis of the scalp

Note: Table 9 columns are SKYRIZI (N=51), placebo (N=54), and the treatment difference (95% CI), in that order. The Week 52 result is from the UnlIMMited Study-S section of the scalp and genital page of the Skyrizi HCP site; all subjects received open-label Skyrizi from Week 16.

Does Skyrizi work for genital psoriasis?

Applies to Adults with moderate-to-severe plaque psoriasis of the genital area

Note: Table 10 columns are SKYRIZI (N=55), placebo (N=54), and the treatment difference (95% CI), in that order. The Week 52 result is from the UnlIMMited Study-G section of the scalp and genital page of the Skyrizi HCP site; all subjects received open-label Skyrizi from Week 16.

Does Skyrizi work for palmoplantar (hand and foot) psoriasis?

Applies to Adults with moderate-to-severe plaque psoriasis

Note: The page shows the IMMprint response rates only in a graphic. The integrated palmoplantar figure (PPASI) comes from a subanalysis of UltIMMa-1 and UltIMMa-2 that the page cites to a 2019 conference poster (Elewski et al.). The Prescribing Information does not report palmoplantar outcomes.

Does Skyrizi improve nail psoriasis?

Applies to Adults with moderate-to-severe plaque psoriasis

Note: The integrated nail figure (NAPSI) comes from a subanalysis of UltIMMa-1 and UltIMMa-2 that the page cites to a 2019 conference poster (Elewski et al.). The Prescribing Information does not report nail outcomes.

Comparisons

Skyrizi vs Stelara (ustekinumab): which was more effective in UltIMMa-1 and UltIMMa-2?

Applies to Adults with moderate-to-severe plaque psoriasis

Note: The comparison page shows the Week 16 PASI 90 and PASI 100 rates vs ustekinumab in a graphic whose values are not in the page text. The Prescribing Information does not report the ustekinumab results.

Skyrizi vs Humira (adalimumab): which was more effective for plaque psoriasis (IMMvent)?

Applies to Adults with moderate-to-severe plaque psoriasis

Note: IMMvent is not described in the Skyrizi Prescribing Information; the result is from the comparison page of the Skyrizi HCP site, which cites Reich et al., Lancet 2019. The page text gives no denominators for these rates.

Skyrizi vs Cosentyx (secukinumab): which was more effective in IMMerge?

Applies to Adults with moderate-to-severe plaque psoriasis

Note: IMMerge is not described in the Skyrizi Prescribing Information; the result is from the comparison page of the Skyrizi HCP site, which cites Warren et al., Br J Dermatol 2021. The page text gives no denominators for these rates.

Skyrizi vs Otezla (apremilast): which was more effective for moderate plaque psoriasis (IMMpulse)?

Applies to Adults with moderate plaque psoriasis who are candidates for systemic therapy

Note: IMMpulse is not described in the Skyrizi Prescribing Information; the result is from the comparison page of the Skyrizi HCP site, which cites Stein Gold et al., Br J Dermatol 2023. The page shows the Week 16 PASI 90 rates in a graphic whose values are not in the page text.

Skyrizi vs Sotyktu (deucravacitinib): which was more effective for moderate plaque psoriasis (IMMpactful)?

Applies to Adults with moderate plaque psoriasis who are candidates for systemic therapy

Note: IMMpactful is not described in the Skyrizi Prescribing Information; the result is from the comparison page of the Skyrizi HCP site, which cites Magnolo et al., Dermatol Ther (Heidelb) 2026. The page shows the Week 16 PASI 90 rates in a graphic whose values are not in the page text.

Long-term results

How many people on Skyrizi still have PASI 90 after 2.5 years?

Applies to Adults with moderate-to-severe plaque psoriasis

Note: These figures are in the section of the comparison page on patients who started and remained on Skyrizi; the page text gives no denominators. The open-label extension data are not in the Prescribing Information.

What skin improvement does Skyrizi show after about 6 years (LIMMitless)?

Applies to Adults with moderate-to-severe plaque psoriasis

Note: The efficacy page shows the Week 304 PASI 90 and PASI 100 rates in a graphic whose values are not in the page text; the open-label extension data are not in the Prescribing Information.